Discusses the role of ANGPTL3 and PCSK9 inhibitors in managing refractory LDL cholesterol in patients with familial hypercholesterolemia.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Seth S. Martin (2020) conducted an editorial in Familial hypercholesterolemia. PCSK9 inhibitors added to statin therapy was evaluated on LDL cholesterol level reduction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: